Sun Pharma Advanced Research Soars 13.3% After U.S. Court Ruling on Sezaby PRV

Sun Pharma Advanced Research Company (SPARC) gained 13.3% after a U.S. court granted summary judgment in its favor over the Sezaby Priority Review Voucher. The ruling strengthens SPARC’s regulatory position, boosts investor confidence, and enhances growth prospects by enabling faster FDA approvals, marking a significant strategic win for the company.

Show more

Stay Ahead – Explore Now! Apis India Ltd Proposes Generous Bonus Share Issue in a 24:1 Ratio to Reward Shareholders